И.Г.Сергеева, Ю.М.Криницына, Н.Г.Макарова, А.А.Дягилева
ФГБОУ ВПО Новосибирский национальный исследовательский государственный университет Минздрава России
1. Nast A, Dreno B, Bettoli V et al. European evidence-based (S3) guidelines for the treatment of acne. J Eur Acad Dermatol Venereol 2012; 26 (1): 1–29.
2. Schafer F, Fich F, Lam M et al. Antimicrobial susceptibility and genetic characteristics of Propionibacterium acnes isolated from patients with acne. Int J Dermatol 2013; 52 (4): 418–25.
3. Surjana D, Damian DL. Nicotinamide in dermatology and photoprotection. Skinmed 2011; 9 (6): 360–5.
4. Fivenson DP. The mechanisms of action of nicotinamide and zinc in inflammatory skin disease. Cutis 2006; 77 (1): 5–10.
5. Grange PA, Raingeaud J, Calvez V, Dupin N. Nicotinamide inhibits Propionibacterium acnes-induced IL-8 production in keratinocytes through the NF-kappaB and MAPK pathways. J Dermatol Sci 2009; 56 (2): 106–12.
6. Namazi MR. Nicotinamide-containing sunscreens for use in Australasian countries and cancer-provoking condition. Med Hypotheses 2003; 60 (4): 544–5.
7. Shalita AR, Smith JG, Parish LC et al. Topical nicotinamide compared with clindamycin gel in the treatment of inflammatory acne vulgaris. Int J Dermatol 1995; 34 (6): 434–7.
8. Бутарева М.М., Знаменская Л.Ф., Каппушева И.А. и др. Принципы комбинированной терапии акне. Вестн. дерматологии и венерологии. 2011; 6: 13–7./